

The Examiner required restriction under 35 U.S.C. 121 to one of the following inventions:

Group 1, claim(s) 1-7, drawn to a method of identifying a compound for the treatment, prevention or diagnosis of a mitoNEET associated dysfunctional disease or condition comprising the steps of determining a direct interaction of compound with mitoNEET.

Group 2, claim(s) 8-10, drawn to a method of treating or preventing a mitoNEET associated a metabolic dysfunctional disease or condition comprising administering a compound that directly interacts with mitoNEET.

Group 3, claim(s) 11, drawn to an antibody that immunospecifically binds the mitoNEET polypeptide.

Group 4, claim(s) 12, drawn to a method of detecting a differentially expressed gene correlated with a mitoNEET associated metabolic dysfunctional disease or condition of a mammalian cell.

Group 5, claim(s) 13, drawn to a method of monitoring the progression of a metabolic disorder in a patient comprising detecting the expression of a marker at a first point in time in a patient and then compare the expression of the marker at a subsequent point in time.


Group 6, claim(s) 14, drawn to a method of assessing the efficacy of a test compound for correcting the metabolic disturbance comprising comparing the expression level of a marker in a sample obtained for a patient after administering a test compound with the expression level of the marker in a second sample from the patient without administering the test compound.

Group 7, claim(s) 15, drawn to a method of selecting a compound for treating, preventing or diagnosing a mitoNEET associated metabolic dysfunctional disease or condition in a patient comprising (i) obtaining a sample cells from a patient, (ii) exposing these cells against plurality of test compounds, (iii) comparing expression level of a marker, and (iv) selecting a test compound that alters the level of a marker expression most.

Applicant elects without traverse the invention of Group I (Claims 1-7)
Applicants reserve the right to file one or more divisional or continuation applications
directed to unelected subject matter.

Further prosecution on the merits is requested.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'S. Christopher Bauer', written over the typed name.

S. Christopher Bauer
Registration No. 42,305
TEL: 314-274-6257
Pharmacia Corporation of
Pfizer Inc
P. O. Box 1027
St. Louis, MO 63006